登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688075 证券简称：安旭生物 公告编号：2026-001 杭州安旭生物科技股份有限公司关于持股5%以上 股东权益变动触及1%刻度的提示性公告 股东马华祥保证向本公司提供的信息真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： ■ 一、信息披露义务人及其一致行动人的基本信息 3.一致行动人信息：无 二、权益变动触及1%刻度的基本情况 公司于2026年1月22日收到股东马华祥出具的《关于减持股份权益变动触及1%的告知函》，2026年1月6 日至2026年1月21日期间，马华祥通过集中竞价的方式减持公司股份804,519股，所持有公司股份数量由 14,773,360股减少至13,968,841股，占公司当前总股本的比例由11.62%减少至10.99%，触及1%的整数 倍，具体情况如下： ■ 注：1、减持股份来源：公司首次公开发行前的股份，并含上市后公司资本公积金转增股本等股份变动 增加的股份； 2、"变动前股数"是指披露《杭州安旭生物科技股份有限公司股东减持股份计划 ...

证券日报网讯 1月22日，安旭生物发布公告称，股东马华祥于2026年1月6日至1月21日通过集中竞价减 持公司804519股，持股比例由11.62%降至10.99%，触及1%刻度。 （文章来源：证券日报） ...

格隆汇1月22日丨安旭生物(688075.SH)公布，公司于2026年1月22日收到股东马华祥出具的《关于减持 股份权益变动触及1%的告知函》，2026年1月6日至2026年1月21日期间，马华祥通过集中竞价的方式减 持公司股份80.45万股，所持有公司股份数量由14,773,360股减少至13,968,841股，占公司当前总股本的 比例由11.62%减少至10.99%，触及1%的整数倍。 ...

证券代码：688075 证券简称：安旭生物 公告编号：2026-001 杭州安旭生物科技股份有限公司关于持股 5%以上 股东权益变动触及 1%刻度的提示性公告 股东马华祥保证向本公司提供的信息真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： | 权益变动方向 | 比例增加□ | 比例减少√ | | --- | --- | --- | | 权益变动前合计比例 | 11.62% | | | 权益变动后合计比例 | 10.99% | | | 本次变动是否违反已作出的承 诺、意向、计划 | 是□ 否√ | | | 是否触发强制要约收购义务 | 是□ 否√ | | 一、 信息披露义务人及其一致行动人的基本信息 1.身份类别 投资者及其一致行动人的身份 □控股股东/实际控制人及其一致行动人 √其他 5%以上大股东及其一致行动人 □合并口径第一大股东及其一致行动人（仅适用 于无控股股东、实际控制人） □其他_______/______（请注明） 2.信息披露义务人信息 | 信息披露义务人名称 | 投资者身份 | 统一社会信用代码 | ...

格隆汇1月22日丨安旭生物(688075.SH)公布，公司于2026年1月22日收到股东马华祥出具的《关于减持 股份权益变动触及1%的告知函》，2026年1月6日至2026年1月21日期间，马华祥通过集中竞价的方式减 持公司股份80.45万股，所持有公司股份数量由14,773,360股减少至13,968,841股，占公司当前总股本的 比例由11.62%减少至10.99%，触及1%的整数倍。 ...

安旭生物公告称，2026年1月6日至21日，持股5%以上股东马华祥通过集中竞价减持804,519股，其持股 数量由1477.3360万股降至1396.8841万股，占总股本比例由11.62%降至10.99%，触及1%整数倍。本次变 动系履行前次减持计划，不触及要约收购，不会导致控股股东及实控人变化，也不影响公司治理和持续 经营。截至公告披露日，马华祥仍处减持计划实施期。 ...

Group 1 - The main point of the news is that the net outflow of main funds in the Shanghai and Shenzhen markets reached 24.126 billion yuan, with the Sci-Tech Innovation Board experiencing a net outflow of 5.449 billion yuan [1] - A total of 224 stocks on the Sci-Tech Innovation Board saw net inflows, while 376 stocks experienced net outflows [1] - Among the stocks with significant net inflows, Haiguang Information led with a net inflow of 457 million yuan, followed by Xinke Mobile-U and Qiangyi Co., with net inflows of 337 million yuan and 323 million yuan respectively [1] Group 2 - There are 56 stocks that have seen continuous net inflows for more than three trading days, with Anxu Bio leading at 10 consecutive days of inflow [2] - The stock with the longest continuous net outflow is Dameng Data, which has seen outflows for 23 consecutive trading days [2] - The top stocks by net inflow include Haiguang Information, Xinke Mobile-U, and Qiangyi Co., with respective inflows of 457.4 million yuan, 337.4 million yuan, and 323.1 million yuan [2][3]

Group 1 - Haitai Xinguang, based in Qingdao, specializes in the research, production, and sales of medical endoscope instruments and optical products, being a leading enterprise in the domestic medical endoscope optical field [1][30] - The company has established long-term collaborations with international medical giants such as Karl Storz and Olympus, and its high-definition optical imaging technology supports navigation equipment for neurosurgery [1][30] - By 2026, the market demand for its high-end optical components is expected to further release due to the recovery of the medical device sector and the advancement of brain-computer interface medical applications [1][30] Group 2 - Huqiang Technology, registered in Yichang, focuses on special protective equipment, pharmaceutical packaging, and medical devices, with a strong advantage in public health emergency material supply [2][31] - Its medical protective equipment is applicable in sterile operating environments for brain-computer interface implantation surgeries, enhancing product competitiveness in the medical device sector [2][31] Group 3 - Zhengde Medical, headquartered in Shaoxing, is a leading enterprise in the medical dressing industry, with a product matrix covering medical dressings, infection control, and rehabilitation care [3][32] - The company's surgical infection control products meet the sterile operation requirements for brain-computer interface implantation surgeries, and its rehabilitation products cater to post-operative patient management needs [3][32] - By 2026, the surgical infection control consumables business is expected to see market growth as brain-computer interface medical applications accelerate [3][32] Group 4 - Linuo Pharmaceutical Packaging, based in Jinan, specializes in the research, production, and sales of pharmaceutical packaging materials, including sterile medical device packaging suitable for brain-computer interface components [4][33] - The company is gradually expanding into the high-end medical device packaging market, seizing opportunities in the brain-computer interface industry [4][33] Group 5 - Rendu Biotech, located in Shanghai, focuses on RNA molecular diagnostic technology, with applications in infection detection post-brain-computer interface implantation surgeries [5][34] - The company’s post-operative infection detection reagents are expected to see new demand growth by 2026 as brain-computer interface clinical surgeries are promoted [5][34] Group 6 - Huangshan Capsule, based in Anhui, specializes in the research and production of pharmaceutical hollow capsules, gradually expanding into medical device auxiliary materials [6][36] - The company’s medical capsule carriers can adapt to the encapsulation needs of sustained-release bioelectrodes in brain-computer interface devices [6][36] Group 7 - ST Kelly, headquartered in Suzhou, focuses on medical device research and production, particularly in ultrasound equipment and rehabilitation devices [7][37] - The company’s ultrasound diagnostic equipment can be used for pre-operative brain tissue imaging assessments in brain-computer interface surgeries [7][37] Group 8 - Aotai Biotech, based in Hangzhou, specializes in rapid diagnostic reagents, with its rapid infection detection reagents applicable in brain-computer interface clinical settings [8][38] - The company is developing rapid detection products for post-operative neurological function assessment related to brain-computer interfaces [8][38] Group 9 - Dongfang Ocean, located in Yantai, focuses on marine biological medical materials, with collagen materials applicable as coatings for brain-computer interface electrodes [9][39] - The company is increasing its R&D investment in the medical device sector, particularly in the integration of biological medical materials with brain-computer interface devices by 2026 [9][39] Group 10 - Shuoshi Biotech, based in Taizhou, specializes in nucleic acid detection technology, with products applicable for precise diagnosis of post-operative brain infections in brain-computer interface surgeries [10][40] - The company is exploring detection technologies related to neurotransmitters in brain-computer interfaces, aiming for breakthroughs in neurological disease diagnostics [10][40] Group 11 - Guofa Co., located in Beihai, focuses on pharmaceutical manufacturing and medical device sales, with a distribution network covering Guangxi and surrounding areas [11][41] - The company plans to increase its agency layout for high-end medical devices related to brain-computer interfaces by 2026 [11][41] Group 12 - Nanwei Co., based in Nantong, specializes in medical dressings and hygiene products, with its adhesive dressings suitable for post-operative care in brain-computer interface surgeries [12][42] - The company is enhancing its R&D on functional medical dressings, launching products tailored for long-term post-operative care in brain-computer interfaces [12][42] Group 13 - Mingde Biotech, located in Wuhan, is a leading enterprise in the field of rapid diagnostic reagents, with products applicable for monitoring vital signs during brain-computer interface surgeries [13][43] - The company is developing rapid assessment devices for post-operative neurological function related to brain-computer interfaces [13][43] Group 14 - Hualan Co., based in Wuxi, specializes in medical rubber products, with its rubber sealing components applicable in fluid control systems for brain-computer interface devices [14][44] - The company is collaborating with research institutions to develop rubber insulation components for brain-computer interface electrodes [14][44] Group 15 - Yuyue Medical, headquartered in Danyang, is a leading enterprise in home medical devices, with products applicable in brain-computer interface surgeries [15][45] - The company is increasing its R&D on medical-grade rehabilitation robots, aiming to integrate brain-computer interface technology with rehabilitation devices [15][45] Group 16 - Shengxiang Biotech, located in Changsha, focuses on nucleic acid detection technology, with products applicable for rapid diagnosis of central nervous system infections post-brain-computer interface surgeries [16][46] - The company is exploring gene detection technologies related to neurological genetic diseases, expanding the application boundaries of molecular diagnostics [16][46] Group 17 - Jiga Development, based in Jinan, focuses on high-end medical device incubation and industrialization, particularly in brain-computer interface-related medical device enterprises [17][47] - The company is responsible for industrial park construction and resource integration for brain-computer interface medical device companies [17][47] Group 18 - Anxu Biotech, located in Hangzhou, specializes in rapid diagnostic reagents, with products applicable for instant infection screening during brain-computer interface surgeries [18][48] - The company is developing rapid detection products for neurotransmitters related to brain-computer interfaces, aiming for breakthroughs in neurological function assessment [18][48] Group 19 - Wantai Biotech, based in Beijing, is a comprehensive enterprise in biopharmaceuticals and medical devices, with products applicable for biochemical index detection post-brain-computer interface surgeries [19][49] - The company is exploring biopharmaceutical development related to brain-computer interfaces, seeking new growth points in nerve repair [19][49] Group 20 - Jiuan Medical, located in Tianjin, focuses on home health devices, with products applicable for synchronized monitoring of brain signals and vital signs in brain-computer interface scenarios [20][50] - The company is increasing its R&D investment in brain-computer interface wearable devices, aiming to create an intelligent medical ecosystem [20][50] Group 21 - Jidan Biotech, based in Nanjing, specializes in POCT reagents and instruments, with products applicable for cardiovascular function assessment in brain-computer interface surgeries [21][51] - The company is developing rapid detection products for post-operative cerebrovascular diseases related to brain-computer interfaces [21][51] Group 22 - Wanfeng Biotech, located in Guangzhou, is a leading enterprise in the POCT field, with products applicable for instant infection screening during brain-computer interface surgeries [22][52] - The company is developing neurobiomarker detection reagents to assess post-operative neurological function recovery, providing comprehensive support for brain-computer interface surgeries [22][52] Group 23 - Haier Biotech, based in Qingdao, specializes in low-temperature storage devices for biological materials, with applications in brain-computer interface-related biological sample preservation [23][53] - The company is increasing its R&D on high-end medical storage devices tailored for brain-computer interface biological materials by 2026 [23][53] Group 24 - Haooubo, located in Suzhou, focuses on immune diagnostic reagents and instruments, with products applicable for immune function assessment in brain-computer interface surgeries [24][54] - The company is developing detection reagents for immune rejection post-brain-computer interface implantation, providing technical support for surgical complications [24][54] Group 25 - Shandong Pharmaceutical Glass, based in Zibo, is a leading enterprise in pharmaceutical glass, with products applicable for insulation packaging of brain-computer interface electrodes [25][55] - The company is expanding into the high-end medical device glass materials market, targeting the brain-computer interface industry [25][55] Group 26 - Innotech, located in Langfang, specializes in infectious disease diagnostic reagents, with products applicable for pre-operative lung infection screening in brain-computer interface surgeries [26][56] - The company is developing rapid detection products for post-operative lung infections related to brain-computer interfaces, aiming for breakthroughs in post-operative complication detection [26][56] Group 27 - Jianer Kang, based in Changzhou, focuses on medical dressings and rehabilitation care products, with its antibacterial medical dressings applicable for post-operative care in brain-computer interface surgeries [27][59] - The company is increasing its R&D on functional medical dressings, launching products tailored for long-term post-operative care in brain-computer interfaces [27][59]

Group 1 - The core viewpoint of the news is that Anxu Bio's financial performance has shown a decline in revenue and net profit, alongside low financing activity and high short-selling levels [1][2]. Group 2 - As of December 24, Anxu Bio's stock price increased by 0.03%, with a trading volume of 12.83 million yuan [1]. - On the same day, the financing buy amount was 1.45 million yuan, while the financing repayment was 2.52 million yuan, resulting in a net financing buy of -1.07 million yuan [1]. - The total financing and securities balance for Anxu Bio reached 94.92 million yuan, which is 1.93% of its market capitalization and below the 40th percentile level over the past year, indicating a low financing position [1]. - In terms of short selling, Anxu Bio had no shares sold or repaid on December 24, with a short selling balance of 0.00 yuan, indicating a high level compared to the 90th percentile over the past year [1]. Group 3 - For the period ending September 30, Anxu Bio reported a total revenue of 325 million yuan, a year-on-year decrease of 19.34%, and a net profit attributable to shareholders of 64.36 million yuan, down 52.60% year-on-year [2]. - The company has distributed a total of 895 million yuan in dividends since its A-share listing, with 657 million yuan distributed over the past three years [2]. - As of September 30, the number of shareholders increased to 6,090, while the average circulating shares per person decreased to 20,867 shares [2]. - Among the top ten circulating shareholders, Guangfa Value Core Mixed A ranked fifth with 3.5645 million shares, an increase of 549,800 shares from the previous period [2].

证券代码：688075 证券简称：安旭生物 公告编号：2025-033 一、 募集资金基本情况 根据中国证券监督管理委员会于 2021 年 9 月 28 日出具的《关于同意杭州安旭生 物科技股份有限公司首次公开发行股票注册的批复》（证监许可〔2021〕3138 号），公 司获准向社会公开发行人民币普通股 15,333,400 股，每股发行价格为人民币 78.28 元， 募集资金总额为 120,029.86 万元；扣除承销及保荐费用、发行登记费以及其他交易费 用共计 14,445.23 万元（不含增值税金额）后，募集资金净额为 105,584.63 万元，上述 资金已全部到位，经信永中和会计师事务所（特殊普通合伙）审验并于 2021 年 11 月 12 日出具了"XYZH/2021HZAA10537"《验资报告》。 募集资金到账后，已全部存放于 经公司董事会批准开设的募集资金专项账户内，公司已与保荐机构、存放募集资金的 银行签署了募集资金三方监管协议。 二、 募集资金管理情况 杭州安旭生物科技股份有限公司 关于部分募集资金账户注销的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重 ...